Category Archives: Eli Lilly

Lilly Launches Glucagon Mobile App

Lilly Diabetes recently launched the free Lilly Glucagon Mobile App to educate those who support people living with type 1 diabetes. The interactive app, available on the iTunes store for iPhone and iPad devices, provides caregivers, diabetes educators, and school nurses with visual and audio emergency instructions, as well as tools to track locations of … Continue reading Lilly Launches Glucagon Mobile App

Boehringer and Lilly Introduce Online Program for Adult Type 2s

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company have introduced My Well Planner, a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health. Sample topics include general information about type 2 diabetes, better eating habits, building physical activity into daily life, … Continue reading Boehringer and Lilly Introduce Online Program for Adult Type 2s

ADA Sessions Spotlight Powerful Weapons Against Diabetes

Several hopeful trends emerged from this year’s ADA Scientific Sessions in Philadelphia, held June 8 through 12. · SGLT2 inhibitors are a class of drugs upon which big pharmaceutical companies are now focusing major attention. In the meantime, other drugs such as Januvia and Bydureon continue battling for market share with robust comparison studies. · … Continue reading ADA Sessions Spotlight Powerful Weapons Against Diabetes

Lilly Begins Sales of Jentadueto, a Combo Drug for Type 2s

Eli Lilly and Company has begun US sales of Jentadueto, a drug for type 2 diabetes that combines Tradjenta and metformin. The drug, in tablet form, is taken twice daily and is available in three prescription strengths. Tradjenta (linagliptin) is a DPP-4 inhibitor that regulates insulin levels. The drug was introduced less than a year … Continue reading Lilly Begins Sales of Jentadueto, a Combo Drug for Type 2s

Afresa: A New Insulin (By the Way, It’s Inhaled)

The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well. But please don’t consider that the final word on … Continue reading Afresa: A New Insulin (By the Way, It’s Inhaled)